Nilotinib
Hypereosinophilic Syndrome
Novartis PharmaceuticalsSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hypereosinophilic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Imatinib Novartis Pharmaceuticals | Phase 2 | B |
Dasatinib M.D. Anderson Cancer Center | Phase 2 | B |
Same molecule, other indications
Nilotinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
74 / 100
View asset →blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →